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To the Editor: 
Dabigatran is a direct thrombin inhibitor characterized by a wide therapeutic 
window, faster onset and offset of action, and no need for routine blood 
monitoring.1 Nonetheless, growing evidence is now available showing that 
interindividual variability exists in the pharmacokinetics of dabigatran, being 
significantly altered by renal dysfunction, patient's age, or comedications.1,2 The 
presence of these conditions, if not adequately taken into account, would 
eventually lead to suboptimal or excessive anticoagulation, with possible 
therapeutic failure or development of adverse drug reactions, including major 
bleeding.3 
Dabigatran is administered as etexilate, a prodrug that is rapidly absorbed and 
quantitatively converted into 2 intermediate prodrugs, namely desethyl dabigatran 
etexilate and dabigatran ethyl-ester (pharmacologically active), which are 
subsequently transformed into dabigatran (Fig. 1).4 Alterations in the bioactivation 
pathway could add further variability to both drug pharmacokinetics and, 
eventually, the response to dabigatran therapy. We have thus investigated the 
mechanism of bioconversion of dabigatran etexilate to dabigatran in vivo in 
patients on maintenance anticoagulation therapy. formatGraphic.tt2 begin   
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A high-performance liquid chromatography coupled with tandem mass 
spectrometry method was developed to measure concomitantly the plasma 
concentrations of dabigatran etexilate, dabigatran, desethyl dabigatran etexilate, 
and dabigatran ethyl-ester based on a recently published assay for dabigatran 
quantification.5 High-purity powder for the preparation of the calibrators of 
dabigatran etexilate was kindly donated by Boeringher Ingelheim (Milan, Italy), 
whereas other compounds were purchased from TRC (Toronto, Canada). Briefly, 
plasma samples were purified by solid phase extraction using C18 Bond Elute 
cartridges. All analytes were quantified by a multiple-reaction monitoring mode 
with the transitions m/z 628.3 > 289.2 for dabigatran etexilate, 472.1 > 289.2 and 
472.1 > 172.0 (confirmation transition) for dabigatran, 603 > 289.2 for desethyl 
dabigatran etexilate, and 500.3 > 289.2 for dabigatran ethyl-ester. The described 
method was validated according to the European Medicines Agency Guidelines for 
bioanalytical method validation.6 For all analytes, the intra- and inter-day 
inaccuracy and imprecision were in every instance <13.4%. For all analytes, the 
lower limit of quantification was set at 1.0 ng/mL (imprecision <=20%). The method 
was subsequently applied for the assessment of plasma trough concentrations of 
dabigatran etexilate, dabigatran, and the 2 intermediate prodrugs in 40 patients on 
maintenance dabigatran etexilate during routine outpatient visits (visits 1, 2, and 3 
respectively at 3, 6, and 12 months after starting anticoagulation therapy). 
A wide interindividual variability of dabigatran plasma trough concentrations was 
observed during the 3 visits (coefficient of variations 86%, 64%, and 62% at visits 
1, 2, and 3, respectively), with measured drug levels (and variability) in the 
expected range according to the available literature.7,8 Interestingly, the prodrug 
dabigatran etexilate was detected in some patients during each visit (Table 1), with 
concentrations ranging from 1 to 15 ng/mL. Similarly, quantifiable concentrations 
of the prodrug intermediates desethyl dabigatran etexilate and dabigatran ethyl-
ester were found overall in 32% and 8% of patients. The presence of these 
intermediates was not linked to the dabigatran dose administered or to single 
patients. Conversely, we found that, when the etexilate prodrug was present, the 
intermediate metabolites were also detected. formatGraphic.tt2 begin   Table 
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As the first finding of this investigation, we confirmed that, despite median 
dabigatran concentrations comparable with values measured in the registrative 
trials, this drug was associated with wide pharmacokinetic interindividual 
variability, in agreement with recent data from real-life settings.7,8 Moreover, the 
characterization of the pharmacokinetics of dabigatran in patients on oral 
anticoagulation therapy we performed reveals the existence of different patterns of 
drug bioactivation, eventually leading to incomplete dabigatran conversion in 
selected cases. Previous studies in healthy volunteers given single dose of 
dabigatran etexilate have shown that this prodrug is rapidly and completely 
converted to dabigatran.9,10 Accordingly, one could expect that dabigatran 
etexilate cannot be found in patients on maintenance anticoagulant therapy. 
Conversely, we observed that 9%–20% of our patients have prodrug 
concentrations above the lower limit of quantification of the method. To better 
evaluate the bioactivation step, we also looked at the 2 main intermediate 
prodrugs, namely desethyl dabigatran etexilate and dabigatran ethyl-ester. Again, 
according to the available literature from healthy male volunteers,4 these 
intermediates are expected to be present, if any, only in trace amounts, given their 
very rapid conversion to dabigatran. According to our data, this may be eventually 
the case for dabigatran ethyl-ester, which was measured only in a minority of 
patients (from 7% to 12%), but not for desethyl dabigatran etexilate, which was 
found in 20%–40% of our patients. Taken together, these findings suggest that 
incomplete bioconversion to dabigatran may take place in selected patients. This 
may be possibly related to inadequate activity of carboxyl esterases (CES1, CES2), 
the class of enzyme involved in the conversion from dabigatran etexilate to 
dabigatran. Indeed, it has been recently shown that the catalytic activity of CES1 
and CES2 can be significantly affected by several factors, such as sex (women 
have higher CES1 activity), age (the activity increases from birth to adulthood), 
drug interactions, hepatic diseases (impaired activity),11 and also by individual 
genetic background.12 
The main limitation of our investigation is represented by the lack of clinical 
information on patients' characteristics (ie, creatinine levels and liver enzymes), as 
well as data on response to therapy (ie, bleeding versus treatment failure). The 
assessment of the potential associations between dabigatran concentrations and 
clinical outcome is beyond the scope of this study. Here, we would like just to give 
a picture of the bioconversion pathway of dabigatran in a real-life scenario. 
In conclusion, different patterns of dabigatran in vivo bioactivation have been 
identified in patients on maintenance anticoagulation therapy. Although the clinical 
impact of these findings warrants future investigations, they might argue against a 
fixed-dose approach for dabigatran, eventually asking for individualized dose 
regimens. 
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